Fresenius SE & Co has patented a method for purifying anti-IL-6 receptor antibodies, specifically tocilizumab, using a three-chromatographic columns procedure. The process involves protein A chromatography, mixed mode chromatography, and a final step with a fluorapatite-based ligand. This innovation aims to produce pharmaceutical compositions with purified antibodies. GlobalData’s report on Fresenius SE & Co gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Fresenius SE & Co, was a key innovation area identified from patents. Fresenius SE & Co's grant share as of April 2024 was 59%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11964998B2) discloses a method for purifying a mono-specific anti-IL-6 receptor antibody, specifically tocilizumab, from a sample containing the antibody and impurities. The method involves a series of steps including contacting the sample with a protein A chromatography material, eluting the antibody, and further purification using mixed mode chromatography materials to remove impurities such as host cell proteins, antibody aggregates, and fragments. The use of specific ligands in the chromatography materials, such as N-benzyl-N-methyl ethanol amine and ceramic fluoroapatite, helps in achieving a high level of purity in the final product.
The method described in the patent is particularly suitable for antibodies produced in recombinant mammalian cells and involves precise conditions for each step of the purification process. For instance, the protein A chromatography material is equilibrated with a specific buffered solution before use, and elution buffers with defined concentrations of acetic acid are employed. Additionally, the mixed mode chromatography materials are also equilibrated with specific buffered solutions to ensure optimal purification efficiency. The inclusion of detailed parameters, such as salt concentrations and pH ranges, in the method highlights the importance of controlled conditions in achieving a purified anti-IL-6 receptor antibody product with minimal impurities. Overall, the patent provides a comprehensive and systematic approach to purifying tocilizumab, offering potential benefits in the production of high-quality antibodies for therapeutic use.
To know more about GlobalData’s detailed insights on Fresenius SE & Co, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
